SARS-CoV-2 S1 Protein RBD (B.1.617 Variant) | abx160088
- Usually shipped in 5 working days
- 1 mg
SARS-CoV-2 S1 Protein RBD (B.1.617 Variant). Cat# abx160088. Supplier: abbexa.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike S1 Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Insect cells.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.617 variant was first identified in India. It contains the E484Q and L452R mutations and is therefore widely known as a "double mutation" variant. These mutations have been reported to increase binding to human ACE2 and reduce antibody neutralization of the virus, in comparison with other variants.
|Target||Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) S1 Protein RBD (B.1.617 Variant)|
|Target Modification||Glu484Gln, Leu452Arg|
|Tested Applications||ELISA, WB|
|Recommended dilutions||Optimal dilutions/concentrations should be determined by the end user.|
|Purity||≥ 90% (SDS-PAGE)|
|Purification||Purified by affinity chromatography.|
|Storage||Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.|
|Molecular Weight||Calculated MW: 26 kDa
Observed MW (12% reducing SDS-PAGE): ~28 kDa
|Sequence Fragment||319-541 AA.|
|Buffer||PBS, pH 7.4. Does not contain preservatives.|
|Directions for use||Centrifuge before opening to ensure complete recovery of vial contents.|
|Availability||Shipped within 5-10 working days.|
|Note||This product is for research use only. This product is shipped with dry ice.|